Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Vaccines Get to America, but Congressional Relief Lacking

Published 12/14/2020, 05:39 AM
Updated 07/09/2023, 06:31 AM

Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down. The Dow, which had an intra-day high of +279 points, wound up closing down 186 points — lower by 0.62% on the day. The S&P 500 saw its fourth straight close in the red, following a strong showing earlier this month and last.

The Nasdaq closed up 0.5% on the day; it had been eyeballing a new all-time closing high, but fell short of that mark. It was led by Tesla (NASDAQ:TSLA) TSLA, +4.5% — one week from its official inclusion in the S&P 500, which will shore up Tesla investment across a wide swath of ETFs and mutual funds — and Alexion ALXN, +35% on reports that it will be bought out at a sizable premium by AstraZeneca (NASDAQ:AZN) AZN. The small-cap Russell 2000 was up 0.11% on the day.

It’s a momentous day in the U.S., as the first Covid-19 front-line workers ceremoniously receive their first doses of the Pfizer PFE-BioNTech BNTX vaccine, but much of the success of the vaccine — indeed, of an outlook toward a pandemic-free global economy — has already been priced into valuations to an extent. The vaccine has rightly received the lion’s share of news headlines today, but it has not dictated the wary tone of market participants — an agreement (or lack thereof) for relief passed through Congress has.

Currently being discussed is the passage of $160 billion in State and Local aid with guardrails for distribution and certain liability protections for employers. What this does not include is any sort of direct stimulus — say, the $1200 one-time checks sent to each household endorsed by Bernie Sanders (I - Vermont), among others — and has a far smaller price tag than what the House had already passed twice, named the Heroes Act. Common sense may lead us to believe some relief is better than none, but common sense doesn’t always have a place at the congressional table.

So if there is a relief bill passed, it will likely be much less robust than many investors had been considering. It would also make very likely the need for further stimulus in 2021, prior to the considered date where every American who wants a Covid-19 vaccine will have one. Only then will we have a true semblance of our old economy back, and not before.

Questions or comments about this article and/or its author? Click here>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Will you retire a millionaire?


One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”


Click to get it free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN): Free Stock Analysis Report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Pfizer Inc. (NYSE:PFE): Free Stock Analysis Report

Tesla, Inc. (TSLA): Free Stock Analysis Report

BioNTech SE Sponsored ADR (NASDAQ:BNTX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.